Clinical trials: multiple sclerosis
Relapsing Remitting Multiple Sclerosis
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
The study is designed to assess the efficacy of Glatiramer Acetate (GA) injection 40 mg administered three times a week compared to placebo in subjects with RRMS, as measured by the number of confirmed relapses during the 12…
- Trial name
- GALA (NCT01067521)
- Testing
- Glatiramer acetate (GA)
- Where
- 176 sites in United States, Bulgaria and 15 more
- Volunteers
- 1,404 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)
The main aim was to study in the real world setting the effectiveness of Cladribine tablets in terms of Annualized Relapse Rate (ARR) and disability progression, in participants who switched from a first line Disease Modifying…
- Trial name
- NCT04934800
- Testing
- Cladribine
- Where
- 61 sites in Austria, Greece and 5 more
- Volunteers
- 256 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
The ACCLAIM study is testing whether the medication "abatacept" can be of benefit to patients with relapsing-remitting multiple sclerosis (MS). Although abatacept is an investigational medication for MS, it is not a new drug.
- Trial name
- ACCLAIM (NCT01116427)
- Testing
- abatacept
- Where
- 21 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Relapsing Remitting Multiple Sclerosis
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
This was a multicenter, randomized, open-label, parallel-group, active-controlled study. Prior to randomization, participants were to have been treated with glatiramer acetate or interferon β-1a (44 μg).
- Trial name
- SURPASS (NCT01058005)
- Testing
- BG00002 (natalizumab), interferon beta-1a, glatiramer acetate
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 84 people
- Sponsor
- Biogen
Multiple Sclerosis
Testosterone Treatment for Multiple Sclerosis
Since men are less likely to develop multiple sclerosis, the hypothesis was that testosterone might be protective in MS. Men with MS for followed untreated for 6 months, followed by a 12 month treatment period with Androgel.
- Trial name
- NCT00405353
- Testing
- Androgel 10 grams of gel containing 100 mg of testosterone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, Los Angeles
Multiple Sclerosis
Pilot Study of Transcranial Direct Current Stimulation (tDCS)
This study will test the tolerability and preliminary efficacy of transcranial direct current stimulation (tDCS) combined with a cognitive training program, remotely-delivered using a telemedicine protocol in 60 adults with…
- Trial name
- NCT02746705
- Testing
- Transcranial Direct Current Stimulation (tDCS), Cognitive Training Program
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- NYU Langone Health
Memory Disorders, Multiple Sclerosis
Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)
The purpose of this crossover trial is to investigate whether atomoxetine (versus placebo) improves memory function in persons with memory deficits due to multiple sclerosis.
- Trial name
- NCT03091400
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Relapsing-Remitting Multiple Sclerosis (RRMS)
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) participants, who switched…
- Trial name
- SUSTAIN (NCT02881567)
- Testing
- Daclizumab
- Where
- 11 sites in United States, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis
Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China
The purpose of this study was to evaluate the efficacy and safety of ofatumumab s.c. in adult participants with relapsing multiple sclerosis (RMS) in China.
- Trial name
- NCT05199571
- Testing
- Ofatumumab
- Where
- 18 sites in China
- Volunteers
- 99 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with PPMS…
- Trial name
- GAVOTTE (NCT04548999)
- Testing
- Ocrelizumab, Antihistamine, Methylprednisolone
- Where
- 147 sites in United States, Argentina and 20 more
- Volunteers
- 769 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis
Primary objective was to assess the effectiveness evaluated by the time to failure of two doses of teriflunomide in comparison to interferon beta-1a in participants with relapsing Multiple Sclerosis [MS].
- Trial name
- TENERE (NCT00883337)
- Testing
- Interferon β-1a, Teriflunomide
- Where
- 54 sites in Belgium, Canada and 11 more
- Volunteers
- 324 people
- Sponsor
- Sanofi
Systemic Sclerosis
A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).
- Trial name
- NCT04744207
- Testing
- GS-248
- Where
- 12 sites in Belgium, Netherlands and 2 more
- Volunteers
- 94 people
- Sponsor
- Gesynta Pharma AB
Relapsing Multiple Sclerosis (RMS)
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
This study evaluated if relapsing multiple sclerosis (MS) participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once monthly could develop an adequate immune response to the COVID-19 mRNA vaccine compared to…
- Trial name
- NCT04878211
- Testing
- Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Raynaud's Disease, Peripheral Vascular Disease
PF-00489791 For The Treatment Of Raynaud's
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
- Trial name
- NCT01090492
- Testing
- PF-00489791
- Where
- 55 sites in United States, Canada and 9 more
- Volunteers
- 243 people
- Sponsor
- Pfizer
Multiple Sclerosis
Tele-Exercise and Multiple Sclerosis
The purpose of this study is to compare the effects of two delivery models of an evidence-based complementary alternative medicine (CAM) program that combines neurorehabilitative (functional) exercise, yoga, and Pilates for…
- Trial name
- TEAMS (NCT03117881)
- Testing
- DirectCAM, TeleCAM, rDirectCAM
- Where
- 40 sites in United States
- Volunteers
- 911 people
- Sponsor
- University of Alabama at Birmingham
Relapsing-remitting Multiple Sclerosis (RRMS)
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS
- Trial name
- ASSESS (NCT01633112)
- Testing
- fingolimod, glatiramer acetate
- Where
- 130 sites in United States, Argentina and 5 more
- Volunteers
- 1,064 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis (MS)
Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)
The objective of this study was to collect data both retrospectively and prospectively in order to evaluate the long-term outcomes, durability of effect, and real-world treatment patterns following treatment with Cladribine…
- Trial name
- NCT03961204
- Testing
- Data Collection
- Where
- 99 sites in United States, Australia and 27 more
- Volunteers
- 662 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
The study is a 24 months randomized, double-blind, Placebo-controlled, multi-center clinical trial with an optional 12 months open label extension.
- Trial name
- REFLEX (NCT00404352)
- Testing
- RNF
- Where
- 67 sites in Argentina, Australia and 25 more
- Volunteers
- 517 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Fatigue
Dalfampridine for Imbalance in Multiple Sclerosis
Dalfampridine is a new medication that was FDA approved in 2010 to improve walking speed in people with Multiple Sclerosis (MS).
- Trial name
- NCT01444300
- Testing
- Dalfampridine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Oregon Health and Science University
Multiple Sclerosis
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
The primary objective of the study is to evaluate the efficacy of BIIB033 in participants with active relapsing multiple sclerosis (MS) when used concurrently with Avonex.
- Trial name
- SYNERGY (NCT01864148)
- Testing
- BIIB033, Avonex
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 419 people
- Sponsor
- Biogen